A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, the ...

About STERIS Company Contact: Julie_Winter@steris.com CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION adversely impact STERIS's provision for income taxes and effective tax rate and subject STERIS to additional income tax in jurisdictions who adopt Pillar Two Model Rules, (g) STERIS's ability to continue to qualify for benefits under certain income tax treaties in light of ratification of more strict income tax treaty rules (through the MLI) in many jurisdictions where STERIS has operations, (h) ...

Earnings Surprise History STERIS plc (STE) is expected to release first-quarter fiscal 2025 results on Aug 6. Healthcare We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS' focus on getting back to normal lead times must have helped it in meeting customer demand. Our model projects the segment's revenues to improve 7.1% from the year-ago reported figure. Within the segment, the ...

STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain these equipments, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. Over the past few quarters, the segment's organic growth has been driven by the continuous procedure volume growth in the United States and favorable pricing and market share gains ...

Meanwhile, the impacts of macroeconomic challenges and increasing consolidation in the industry pose a worry for the stock. The renowned provider of infection prevention and other procedural products and services has a market capitalization of $21.75 billion. The company has an earnings yield of 4.20% compared to the industry's -5.82%. In the trailing four quarters, STE delivered an average earnings surprise of 2.21%. Factors at Play Optimistic Forecast for the AST Segment: The business offers a wide range ...

STERIS' (STE) strong rebound of procedure volumes in the United States is leading to solid growth in the Healthcare business. Yet, a fiercely competitive market offsets the positive. The stock carries a Zacks Rank #3 (Hold) at present. STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource i ...

It has been about a month since the last earnings report for Steris (STE) . Shares have added about 2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Steris due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. STERIS Q4 Earnings Match Estimates, Margins Crash STERIS ...

AUSTIN, Texas, June 3, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private equity firm, announced today that it has completed the previously announced acquisition of the dental segment ("HuFriedyGroup" or the "Company") of STERIS plc (NYSE:STE) ("STERIS"). Founded in 1908, HuFriedyGroup is a leading global manufacturer of high-quality instruments, infection prevention products, instrument management systems, and conscious sedation products for the dental ind ...

United States Securities and Exchange Commission Washington, D. C. 20549 ________________________________________________ Commission file number 001-38848 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-1455064 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction ...

Did you analyze how Steris (STE) fared in its international operations for the quarter ending March 2024? Given the widespread global presence of this medical products maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place gr ...